Evidence map›Paper›PMID 35621938›Full record

ArticleMarine drugs2022

Comprehensive Genomic Analysis of Marine Strain

Xu Hu, Yuqi Tang, Yuanyuan Liu, Xinwei Pei, Ziwei Huang, Fuhang Song, Huawei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xu HuSchool of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
Yuqi TangSchool of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
Yuanyuan LiuSchool of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
Xinwei PeiSchool of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
Ziwei HuangSchool of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
Fuhang SongSchool of Light Industry, Beijing Technology and Business University, Beijing 100048, China.ORCID 0000-0002-9162-3355
Huawei ZhangSchool of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0002-2430-3845

Funding

Fundamental Research Fund for the Provincial Universities of Zhejiang RF-C2019002National Key Research and Development Program of China 2018YFC0311004National Natural Science Foundation of China 41776139
6 · The paper itself

Abstract

Chrysomycin A is one of the most promising therapeutic candidates for treating infections caused by multidrug-resistant Gram-positive bacteria. By hybridizing next-step generation (Illumina) and third-generation (PacBio) sequencing technologies, a high-quality chromosome-level genome together with a plasmid was firstly assembled for chrysomycin A-producing marine strain 891. Phylogenetic analysis of the 16

Indexed as

StreptomycesAminoglycosidesGenomicsPhylogenyRNA, Ribosomal, 16SAminoglycosideschrysomycin ARNA, Ribosomal, 16Schrysomycin Agene miningmarine strainStreptomyceswhole-genome

Identifiers

PMID35621938
PMCPMC9144908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.